Is The CoolSculpting Mini A Hit Or Miss?

I first wrote about the CoolSculpting Mini in August 2015. There was a lot of excitement over the new hand piece that was being promoted for smaller areas of the body, such as under the chin and for upper arm fat reduction. So how’s the CoolSculpting Mini doing?

The main problem isn’t the destruction of the fat cells – CoolSculpting and the CoolSculpting Mini does a great job with that. The biggest complaint quickly became reports of the treatments causing laxity to the skin in the treated area. The fat was gone, but an almost bigger problem replaced it.

This would not have been good news for Allergan, mostly known as the owners of Botox Cosmetic and Juvederm. Allergan finalized the purchase of Zeltiq (owners of CoolSculpting) for a cool $2.48 billion this past April.

Luckily for Allergan, and thousands of doctors who now offer CoolSculpting treatments, it is incorrect patient selection that is the problem and not the treatment itself.

This is where the clinics offering all CoolSculpting treatments must educate their staff on proper patient selection. Trust me when I say that being honest and telling a patient that they are not a candidate for this particular treatment is a whole lot easier than treating the patient and leaving them with loose, hanging skin.

Proper patient selection is a must for every treatment offered – otherwise you will not only be refunding a lot of money, but also endangering your reputation.

If you are interested in the CoolSculpting treatments for yourself, make sure that you are being realistic about the final outcome. Remember, if it sounds too good to be true then it probably is.

 

Until next time….

Leave a Reply